Lv5
1170 积分 2023-04-25 加入
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
2天前
已完结
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial
27天前
已关闭
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer
27天前
已关闭
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
27天前
已完结
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer
28天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
1个月前
已完结
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
2个月前
已完结
Adebrelimab versus serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis in China
2个月前
已完结
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
2个月前
已完结
Phase I Studies of HLX26, A Novel Anti-LAG-3 Antibody, Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors
2个月前
已关闭
皖公网安备34019202002308
